Sodium salicylate is a novel catalytic inhibitor of human DNA topoisomerase II alpha

Biochemical Pharmacology

Volumn 81, Issue 3, 2011, Pages 345-354

  Bau, Jason T ^a   Kurz, Ebba U ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Catalytic inhibitor; DNA damage signalling; Doxorubicin; Sodium salicylate; Topoisomerase II

Indexed keywords

ATM PROTEIN; BENZOIC ACID; CHECKPOINT KINASE 2; CYCLOOXYGENASE 2; DNA TOPOISOMERASE; DNA TOPOISOMERASE II ALPHA; DOUBLE STRANDED DNA; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P53; SALICYLATE SODIUM; SERINE; TROLOX C; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CATALYSIS; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA CLEAVAGE; DNA DAMAGE; DNA STRAND BREAKAGE; DRUG CYTOTOXICITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIGENS, NEOPLASM; CATALYSIS; CELL LINE, TUMOR; DNA DAMAGE; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DOXORUBICIN; ENZYME INHIBITORS; ETOPOSIDE; FREE RADICAL SCAVENGERS; HUMANS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; SODIUM SALICYLATE; TRANSCRIPTION, GENETIC;

EID: 78650684679     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.10.009     Document Type: Article

References (38)

1. J.C. Wang DNA topoisomerases Annu Rev Biochem 65 1996 635 692
2. D.A. Burden, and N. Osheroff Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme Biochim Biophys Acta 1400 1998 139 154
3. J.L. Nitiss DNA topoisomerase II and its growing repertoire of biological functions Nat Rev Cancer 9 2009 327 337
4. J.L. Nitiss Targeting DNA topoisomerase II in cancer chemotherapy Nat Rev Cancer 9 2009 338 350
5. B.A. Chabner, P.C. Amrein, B.J. Druker, M.D. Michaelson, C.S. Mitsiades, and P.E. Goss Antineoplastic agents L.L. Brunton, J.S. Lazo, K.L. Parker, Goodman & Gilman's the pharmacological basis of therapeutics 2009 The McGraw-Hill Companies
6. E.U. Kurz, P. Douglas, and S.P. Lees-Miller Doxorubicin activates ATM-dependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species J Biol Chem 279 2004 53272 53281
7. B.V. Jensen Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer Semin Oncol 33 2006 S15 S21
8. Rasband WS. ImageJ. Bethesda, MD, USA: U.S. National Institutes of Health. http://rsb.info.nih.gov/ij/1997-2009.
9. D. Subramanian, C.S. Furbee, and M.T. Muller ICE bioassay. Isolating in vivo complexes of enzyme to DNA Methods Mol Biol 95 2001 137 147
10. T.G. Gantchev, and D.J. Hunting The ortho-quinone metabolite of the anticancer drug etoposide (VP-16) is a potent inhibitor of the topoisomerase II/DNA cleavable complex Mol Pharmacol 53 1998 422 428
11. E.U. Kurz, K.B. Leader, D.J. Kroll, M. Clark, and F. Gieseler Modulation of human DNA topoisomerase IIalpha function by interaction with 14-3-3epsilon J Biol Chem 275 2000 13948 13954
12. R.K. Baker, E.U. Kurz, D.W. Pyatt, R.D. Irons, and D.J. Kroll Benzene metabolites antagonize etoposide-stabilized cleavable complexes of DNA topoisomerase IIalpha Blood 98 2001 830 833
13. A. Cervantes, H.M. Pinedo, J. Lankelma, and G.J. Schuurhuis The role of oxygen-derived free radicals in the cytotoxicity of doxorubicin in multidrug resistant and sensitive human ovarian cancer cells Cancer Lett 41 1988 169 177
14. M.V. Chernov, and G.R. Stark The p53 activation and apoptosis induced by DNA damage are reversibly inhibited by salicylate Oncogene 14 1997 2503 2510
15. S.M. DeAtley, M.Y. Aksenov, M.V. Aksenova, B. Harris, R. Hadley, and H.P. Cole Antioxidants protect against reactive oxygen species associated with adriamycin-treated cardiomyocytes Cancer Lett 136 1999 41 46
16. J.B. Johnston, L.A. Zwelling, D. Kerrigan, L.S. Lloyd, and R.I. Glazer Comparison of DNA scission and cytotoxicity produced by Adriamycin and 5-iminodaunorubicin in human colon carcinoma cells Biochem Pharmacol 32 1983 2255 2258
17. G.L. Tong, D.W. Henry, and E.M. Acton 5-Iminodaunorubicin. Reduced cardiotoxic properties in an antitumor anthracycline J Med Chem 22 1979 36 39
18. M.F. Lavin, and S. Kozlov ATM activation and DNA damage response Cell Cycle 6 2007 931 942
19. E.U. Kurz, and S.P. Lees-Miller DNA damage-induced activation of ATM and ATM-dependent signaling pathways DNA Repair (Amst) 3 2004 889 900
20. J.R. Vane, and R.M. Botting Mechanism of action of nonsteroidal anti-inflammatory drugs Am J Med 104 1988 2S 8S
21. E. Kopp, and S. Ghosh Inhibition of NF-kappa B by sodium salicylate and aspirin Science 265 1994 956 959
22. M.J. Yin, Y. Yamamoto, and R.B. Gaynor The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta Nature 396 1998 77 80
23. N.D. Horton, S.S. Biswal, L.L. Corrigan, J. Bratta, and J.P. Kehrer Acrolein causes inhibitor kappaB-independent decreases in nuclear factor kappaB activation in human lung adenocarcinoma (A549) cells J Biol Chem 274 1999 9200 9206
24. H. Lou, and N. Kaplowitz Glutathione depletion down-regulates tumor necrosis factor alpha-induced NF-kappaB activity via IkappaB kinase-dependent and -independent mechanisms J Biol Chem 282 2007 29470 29481
25. J.L. Hillson, D.E. Furst, and Rofecoxib Expert Opin Pharmacother 1 2000 1053 1066
26. K. Tanabe, Y. Ikegami, R. Ishida, and T. Andoh Inhibition of topoisomerase II by antitumour agents bis(2,6-dioxopiperazine) derivatives Cancer Res 51 1991 4903 4908
27. J.R. Fan, T.H. Huang, C.Y. Wen, T.L. Shen, and T.K. Li Sodium salicylate acts through direct inhibition of phosphoinositide 3-kinase-like kinases to modulate topoisomerase-mediated DNA damage responses Eur J Pharmacol 638 2010 13 20
28. D.E. Marra, T. Simoncini, and J.K. Liao Inhibition of vascular smooth muscle cell proliferation by sodium salicylate mediated by upregulation of p21(Waf1) and p27(Kip1) Circulation 102 2000 2124 2130
29. D.E. Marra, and J.K. Liao Salicylates and vascular smooth muscle cell proliferation: molecular mechanisms for cell cycle arrest Trends Cardiovasc Med 11 2001 339 344
30. L.M.G. Antunes, R.B.L. Bueno, F.L. Diaz, and M.L.P. Bianchi Acetylsalicylic acid exhibits anticlastogenic effects on cultured human lymphocytes exposed to doxorubicin Mutat Res 626 2007 155 161
31. P. Ricchi, T. Di Matola, G. Ruggiero, D. Zanzi, A. Apicella, and A. di Palma Effect of non-steroidal anti-inflammatory drugs on colon carcinoma Caco-2 cell responsiveness to topoisomerase inhibitor drugs Br J Cancer 86 2002 1501 1509
32. A.K. Larsen, A.E. Escargueil, and A. Skladanowski Catalytic topoisomerase II inhibitors in cancer therapy Pharmacol Ther 99 2003 167 181
33. J.F. Ward DNA damage produced by ionizing radiation in mammalian cells: identities, mechanisms of formation, and reparability Prog Nucleic Acid Res Mol Biol 35 1988 95 125
34. C. Nakanishi, and M. Toi Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs Nat Rev Cancer 5 2005 297 309
35. A. Burke, E.M. Smyth, and G.A. FitzGerald Analgesic-antipyretic and anti-inflammatory agents: pharmacotherapy of gout L.L. Brunton, J.S. Lazo, K.L. Parker, Goodman & Gilman's the pharmacological basis of therapeutics 2009 The McGraw-Hill Companies
36. J. Koska, E. Ortega, J.C. Bunt, A. Gasser, J. Impson, and R.L. Hanson The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study Diabetologia 52 2009 385 393
37. S.N. van der Crabben, G. Allick, M.T. Ackermans, E. Endert, J.A. Romijn, and H.P. Sauerwein Prolonged fasting induces peripheral insulin resistance, which is not ameliorated by high-dose salicylate Am J Physiol Endocrinol Metab 297 2009 E1205 E1211
38. L.A. Stark, K. Reid, O.J. Sansom, F.V. Din, S. Guichard, and I. Mayer Aspirin activates the NF-kappaB signalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer Carcinogenesis 28 2007 968 976